Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03897205 · ClinicalTrials.gov registry record · Phase 2
An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients
A Phase 2 study, sponsored by Hansa Biopharma AB.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT03897205 is a Phase 2 study that has completed, run by Hansa Biopharma AB. The registered enrollment target is 30 participants.
The verdict
NCT03897205, a Phase 2 study, has completed, sponsored by Hansa Biopharma AB.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study was to investigate how efficiently the study medication imlifidase reduces the amount of donor specific antibodies (DSA) in comparison with plasma exchange (PE) therapy, in patients who have had an active or chronic active antibody mediated rejection (AMR) after being kidney transplanted. The purpose was also to investigate and compare safety for these two treatments.
Interventions
- DRUG Imlifidase
- OTHER Plasma Exchange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-04-30 |
| Est. Completion | 2022-11-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03897205
The ClinicalTrials.gov registry entry for NCT03897205 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hansa Biopharma AB, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Imlifidase is the first listed.
NCT03897205 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03897205 about?
NCT03897205 is a clinical study titled "An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients". The purpose of this study was to investigate how efficiently the study medication imlifidase reduces the amount of donor specific antibodies (DSA) in comparison with plasma exchange (PE) therapy, in patients who have had an active or chronic active antibody mediated rejection (AMR) after being kidne...
What is the current status of trial NCT03897205?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2019-04-30. Estimated completion is 2022-11-16.
What interventions are being tested in trial NCT03897205?
The interventions under investigation include: Imlifidase (DRUG), Plasma Exchange (OTHER).
Who is sponsoring clinical trial NCT03897205?
This trial is sponsored by Hansa Biopharma AB, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.